Tyra Biosciences (TYRA) Free Cash Flow (2020 - 2026)
Tyra Biosciences (TYRA) posted Free Cash Flow of -$32.7 million for Q1 2026, down 37.99% on a QoQ basis from -$23.7 million in Q4 2025, and down 28.29% year-over-year from -$45.5 million in Q1 2025.
Tyra Biosciences (TYRA) Free Cash Flow (2020 - 2026) Analysis & Trends
Tyra Biosciences' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$32.7 million for Q1 2026.
- Quarterly Free Cash Flow fell 28.29% year-over-year to -$32.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.4 million (down 38.9% YoY) and the FY2025 annual result came in at -$95.2 million, down 35.17% from the prior year.
- Free Cash Flow was -$32.7 million for Q1 2026 at Tyra Biosciences, down from -$23.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.2 million in Q1 2022 and bottomed at -$32.7 million in Q1 2026.
- A 5-year average of -$17.6 million and a median of -$17.3 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 274.6% — and 2023, when it soared 43.01%.
- Tyra Biosciences' Free Cash Flow stood at -$12.0 million in 2022, then fell by 18.08% to -$14.1 million in 2023, then plunged by 38.63% to -$19.6 million in 2024, then retreated by 20.77% to -$23.7 million in 2025, then slumped by 37.99% to -$32.7 million in 2026.
- Business Quant data shows TYRA's Free Cash Flow at -$32.7 million in Q1 2026, -$23.7 million in Q4 2025, and -$22.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Tyra Biosciences | 1.90 Bn | 1.90 Bn | - | -32.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.66 Mn |
| Mar 31, 2026 | -32.66 Mn |
| Dec 31, 2025 | -23.67 Mn |
| Dec 31, 2025 | -23.67 Mn |
| Sep 30, 2025 | -22.36 Mn |
| Sep 30, 2025 | -22.36 Mn |
| Jun 30, 2025 | -23.73 Mn |
| Jun 30, 2025 | -23.73 Mn |
| Mar 31, 2025 | -25.46 Mn |
| Mar 31, 2025 | -25.46 Mn |
| Dec 31, 2024 | -19.60 Mn |
| Dec 31, 2024 | -19.60 Mn |
| Sep 30, 2024 | -18.52 Mn |
| Sep 30, 2024 | -18.52 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Jun 30, 2024 | -10.16 Mn |
| Mar 31, 2024 | -22.16 Mn |
| Mar 31, 2024 | -22.16 Mn |
| Dec 31, 2023 | -14.14 Mn |
| Dec 31, 2023 | -14.14 Mn |